ERBB2 and breast cancer: In 2009, everolimus received approval from the FDA for HER2-negative breast cancer (advanced HR+ BC) patients in combination with exemestane after failure of a nonsteroidal aromatase inhibitor (Afinitor: Highlights of Prescribing Information).